APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Glycopeptide Antibiotics

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Glycopeptide Antibiotics Market Analysis and Forecast 2026-2032

Report ID 17399593022 January 2026191 pages

Choose your research edition.

Industry ResearchGlycopeptide Antibiotics Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Glycopeptide Antibiotics Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Glycopeptide Antibiotics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Glycopeptide Antibiotics Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Glycopeptide Antibiotics Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Glycopeptide Antibiotics market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Glycopeptide Antibiotics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Glycopeptide Antibiotics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Glycopeptide Antibiotics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Glycopeptide Antibiotics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Glycopeptide Antibiotics include Allergan, Alvogen, ANI Pharmaceuticals, Aurobindo Pharma, Hikma Pharmaceuticals plc, Lytix Biopharma, Theravance Biopharma, Eli Lilly and Company and Shenwei Pharmaceutical, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Glycopeptide Antibiotics, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Glycopeptide Antibiotics, also provides the revenue of main regions and countries. Of the upcoming market potential for Glycopeptide Antibiotics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Glycopeptide Antibiotics revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Glycopeptide Antibiotics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Glycopeptide Antibiotics revenue, projected growth trends, production technology, application and end-user industry.

Glycopeptide Antibiotics Segment by Company

Allergan

Alvogen

ANI Pharmaceuticals

Aurobindo Pharma

Hikma Pharmaceuticals plc

Lytix Biopharma

Theravance Biopharma

Eli Lilly and Company

Shenwei Pharmaceutical

Zhejiang Hisun Pharmaceutical Co., Ltd.

Glycopeptide Antibiotics Segment by Type

Vancomycin

Teicoplanin

Bleomycin

Glycopeptide Antibiotics Segment by Application

Enterococcus Treatment

Staphylococcus Aureus Treatment

Glycopeptide Antibiotics Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Glycopeptide Antibiotics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Glycopeptide Antibiotics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Glycopeptide Antibiotics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Glycopeptide Antibiotics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Glycopeptide Antibiotics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Glycopeptide Antibiotics revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Glycopeptide Antibiotics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Vancomycin Major Player Table 3. Teicoplanin Major Player Table 4. Bleomycin Major Player Table 5. Global Glycopeptide Antibiotics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Enterococcus Treatment Major Player Table 7. Staphylococcus Aureus Treatment Major Player Table 8. Glycopeptide Antibiotics Industry Trends Table 9. Glycopeptide Antibiotics Industry Drivers Table 10. Glycopeptide Antibiotics Industry Opportunities and Challenges Table 11. Glycopeptide Antibiotics Industry Restraints Table 12. Global Glycopeptide Antibiotics Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Glycopeptide Antibiotics Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Glycopeptide Antibiotics Market Share by Region (2021-2026) Table 15. Global Glycopeptide Antibiotics Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Glycopeptide Antibiotics Market Share by Region (2027-2032) Table 17. Global Glycopeptide Antibiotics Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Glycopeptide Antibiotics Revenue Market Share by Players (2021-2026) Table 19. Global Glycopeptide Antibiotics Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Glycopeptide Antibiotics Key Players Headquarters & Area Served Table 21. Global Glycopeptide Antibiotics Players, Product Type & Application Table 22. Global Glycopeptide Antibiotics Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Glycopeptide Antibiotics by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Glycopeptide Antibiotics Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Glycopeptide Antibiotics Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Glycopeptide Antibiotics Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Glycopeptide Antibiotics Revenue Market Share by Type (2021-2026) Table 29. Global Glycopeptide Antibiotics Revenue Market Share by Type (2027-2032) Table 30. Global Glycopeptide Antibiotics Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Glycopeptide Antibiotics Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Glycopeptide Antibiotics Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Glycopeptide Antibiotics Revenue Market Share by Application (2021-2026) Table 34. Global Glycopeptide Antibiotics Revenue Market Share by Application (2027-2032) Table 35. Allergan Company Information Table 36. Allergan Business Overview Table 37. Allergan Glycopeptide Antibiotics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Allergan Glycopeptide Antibiotics Product Portfolio Table 39. Allergan Recent Development Table 40. Alvogen Company Information Table 41. Alvogen Business Overview Table 42. Alvogen Glycopeptide Antibiotics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Alvogen Glycopeptide Antibiotics Product Portfolio Table 44. Alvogen Recent Development Table 45. ANI Pharmaceuticals Company Information Table 46. ANI Pharmaceuticals Business Overview Table 47. ANI Pharmaceuticals Glycopeptide Antibiotics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. ANI Pharmaceuticals Glycopeptide Antibiotics Product Portfolio Table 49. ANI Pharmaceuticals Recent Development Table 50. Aurobindo Pharma Company Information Table 51. Aurobindo Pharma Business Overview Table 52. Aurobindo Pharma Glycopeptide Antibiotics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Aurobindo Pharma Glycopeptide Antibiotics Product Portfolio Table 54. Aurobindo Pharma Recent Development Table 55. Hikma Pharmaceuticals plc Company Information Table 56. Hikma Pharmaceuticals plc Business Overview Table 57. Hikma Pharmaceuticals plc Glycopeptide Antibiotics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Hikma Pharmaceuticals plc Glycopeptide Antibiotics Product Portfolio Table 59. Hikma Pharmaceuticals plc Recent Development Table 60. Lytix Biopharma Company Information Table 61. Lytix Biopharma Business Overview Table 62. Lytix Biopharma Glycopeptide Antibiotics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Lytix Biopharma Glycopeptide Antibiotics Product Portfolio Table 64. Lytix Biopharma Recent Development Table 65. Theravance Biopharma Company Information Table 66. Theravance Biopharma Business Overview Table 67. Theravance Biopharma Glycopeptide Antibiotics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Theravance Biopharma Glycopeptide Antibiotics Product Portfolio Table 69. Theravance Biopharma Recent Development Table 70. Eli Lilly and Company Company Information Table 71. Eli Lilly and Company Business Overview Table 72. Eli Lilly and Company Glycopeptide Antibiotics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Eli Lilly and Company Glycopeptide Antibiotics Product Portfolio Table 74. Eli Lilly and Company Recent Development Table 75. Shenwei Pharmaceutical Company Information Table 76. Shenwei Pharmaceutical Business Overview Table 77. Shenwei Pharmaceutical Glycopeptide Antibiotics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Shenwei Pharmaceutical Glycopeptide Antibiotics Product Portfolio Table 79. Shenwei Pharmaceutical Recent Development Table 80. Zhejiang Hisun Pharmaceutical Co., Ltd. Company Information Table 81. Zhejiang Hisun Pharmaceutical Co., Ltd. Business Overview Table 82. Zhejiang Hisun Pharmaceutical Co., Ltd. Glycopeptide Antibiotics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Zhejiang Hisun Pharmaceutical Co., Ltd. Glycopeptide Antibiotics Product Portfolio Table 84. Zhejiang Hisun Pharmaceutical Co., Ltd. Recent Development Table 85. North America Glycopeptide Antibiotics Revenue by Type (2021-2026) & (US$ Million) Table 86. North America Glycopeptide Antibiotics Revenue by Type (2027-2032) & (US$ Million) Table 87. North America Glycopeptide Antibiotics Revenue by Application (2021-2026) & (US$ Million) Table 88. North America Glycopeptide Antibiotics Revenue by Application (2027-2032) & (US$ Million) Table 89. North America Glycopeptide Antibiotics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 90. North America Glycopeptide Antibiotics Revenue by Country (2021-2026) & (US$ Million) Table 91. North America Glycopeptide Antibiotics Revenue by Country (US$ Million) & (2027-2032) Table 92. Europe Glycopeptide Antibiotics Revenue by Type (2021-2026) & (US$ Million) Table 93. Europe Glycopeptide Antibiotics Revenue by Type (2027-2032) & (US$ Million) Table 94. Europe Glycopeptide Antibiotics Revenue by Application (2021-2026) & (US$ Million) Table 95. Europe Glycopeptide Antibiotics Revenue by Application (2027-2032) & (US$ Million) Table 96. Europe Glycopeptide Antibiotics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 97. Europe Glycopeptide Antibiotics Revenue by Country (2021-2026) & (US$ Million) Table 98. Europe Glycopeptide Antibiotics Revenue by Country (US$ Million) & (2027-2032) Table 99. China Glycopeptide Antibiotics Revenue by Type (2021-2026) & (US$ Million) Table 100. China Glycopeptide Antibiotics Revenue by Type (2027-2032) & (US$ Million) Table 101. China Glycopeptide Antibiotics Revenue by Application (2021-2026) & (US$ Million) Table 102. China Glycopeptide Antibiotics Revenue by Application (2027-2032) & (US$ Million) Table 103. Asia Glycopeptide Antibiotics Revenue by Type (2021-2026) & (US$ Million) Table 104. Asia Glycopeptide Antibiotics Revenue by Type (2027-2032) & (US$ Million) Table 105. Asia Glycopeptide Antibiotics Revenue by Application (2021-2026) & (US$ Million) Table 106. Asia Glycopeptide Antibiotics Revenue by Application (2027-2032) & (US$ Million) Table 107. Asia Glycopeptide Antibiotics Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 108. Asia Glycopeptide Antibiotics Revenue by Region (US$ Million) & (2021-2026) Table 109. Asia Glycopeptide Antibiotics Revenue by Region (US$ Million) & (2027-2032) Table 110. SAMEA Glycopeptide Antibiotics Revenue by Type (2021-2026) & (US$ Million) Table 111. SAMEA Glycopeptide Antibiotics Revenue by Type (2027-2032) & (US$ Million) Table 112. SAMEA Glycopeptide Antibiotics Revenue by Application (2021-2026) & (US$ Million) Table 113. SAMEA Glycopeptide Antibiotics Revenue by Application (2027-2032) & (US$ Million) Table 114. SAMEA Glycopeptide Antibiotics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 115. SAMEA Glycopeptide Antibiotics Revenue by Country (2021-2026) & (US$ Million) Table 116. SAMEA Glycopeptide Antibiotics Revenue by Country (US$ Million) & (2027-2032) Table 117. Research Programs/Design for This Report Table 118. Authors List of This Report Table 119. Secondary Sources Table 120. Primary Sources List of Figures Figure 1. Glycopeptide Antibiotics Image Figure 2. Global Glycopeptide Antibiotics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Glycopeptide Antibiotics Market Size Share 2021 VS 2025 VS 2032 Figure 4. Vancomycin Image Figure 5. Teicoplanin Image Figure 6. Bleomycin Image Figure 7. Global Glycopeptide Antibiotics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Glycopeptide Antibiotics Market Size Share 2021 VS 2025 VS 2032 Figure 9. Enterococcus Treatment Image Figure 10. Staphylococcus Aureus Treatment Image Figure 11. Global Glycopeptide Antibiotics Market Size (US$ Million) & (2021-2032) Figure 12. Global Glycopeptide Antibiotics Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Glycopeptide Antibiotics Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Glycopeptide Antibiotics Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Glycopeptide Antibiotics Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Glycopeptide Antibiotics Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Glycopeptide Antibiotics Revenue Market Share by Type (2021-2032) Figure 19. Global Glycopeptide Antibiotics Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Glycopeptide Antibiotics Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Glycopeptide Antibiotics Revenue Market Share by Application (2021-2032) Figure 22. North America Glycopeptide Antibiotics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Glycopeptide Antibiotics Revenue Share by Type (2021-2032) Figure 24. North America Glycopeptide Antibiotics Revenue Share by Application (2021-2032) Figure 25. North America Glycopeptide Antibiotics Revenue Share by Country (2021-2032) Figure 26. United States Glycopeptide Antibiotics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Glycopeptide Antibiotics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Glycopeptide Antibiotics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Glycopeptide Antibiotics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Glycopeptide Antibiotics Revenue Share by Type (2021-2032) Figure 31. Europe Glycopeptide Antibiotics Revenue Share by Application (2021-2032) Figure 32. Europe Glycopeptide Antibiotics Revenue Share by Country (2021-2032) Figure 33. Germany Glycopeptide Antibiotics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Glycopeptide Antibiotics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Glycopeptide Antibiotics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Glycopeptide Antibiotics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Glycopeptide Antibiotics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Glycopeptide Antibiotics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Glycopeptide Antibiotics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Glycopeptide Antibiotics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Glycopeptide Antibiotics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Glycopeptide Antibiotics Revenue Share by Type (2021-2032) Figure 43. China Glycopeptide Antibiotics Revenue Share by Application (2021-2032) Figure 44. Asia Glycopeptide Antibiotics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Glycopeptide Antibiotics Revenue Share by Type (2021-2032) Figure 46. Asia Glycopeptide Antibiotics Revenue Share by Application (2021-2032) Figure 47. Asia Glycopeptide Antibiotics Revenue Share by Region (2021-2032) Figure 48. Japan Glycopeptide Antibiotics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Glycopeptide Antibiotics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Glycopeptide Antibiotics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Glycopeptide Antibiotics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Glycopeptide Antibiotics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Glycopeptide Antibiotics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Glycopeptide Antibiotics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Glycopeptide Antibiotics Revenue Share by Type (2021-2032) Figure 56. SAMEA Glycopeptide Antibiotics Revenue Share by Application (2021-2032) Figure 57. SAMEA Glycopeptide Antibiotics Revenue Share by Country (2021-2032) Figure 58. Brazil Glycopeptide Antibiotics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Glycopeptide Antibiotics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Glycopeptide Antibiotics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Glycopeptide Antibiotics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Glycopeptide Antibiotics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Glycopeptide Antibiotics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Glycopeptide Antibiotics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Glycopeptide Antibiotics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Glycopeptide Antibiotics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Glycopeptide Antibiotics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Glycopeptide Antibiotics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Vancomycin
  • Teicoplanin
  • Bleomycin
Applications
  • Enterococcus Treatment
  • Staphylococcus Aureus Treatment
Companies covered
  • Allergan
  • Alvogen
  • ANI Pharmaceuticals
  • Aurobindo Pharma
  • Hikma Pharmaceuticals plc
  • Lytix Biopharma
  • Theravance Biopharma
  • Eli Lilly and Company
  • Shenwei Pharmaceutical
  • Zhejiang Hisun Pharmaceutical Co., Ltd.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Glycopeptide Antibiotics Market by Type
  3. 1.2.1 Global Glycopeptide Antibiotics Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Vancomycin
  5. 1.2.3 Teicoplanin
  6. 1.2.4 Bleomycin
  7. 1.3 Glycopeptide Antibiotics Market by Application
  8. 1.3.1 Global Glycopeptide Antibiotics Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Enterococcus Treatment
  10. 1.3.3 Staphylococcus Aureus Treatment
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Glycopeptide Antibiotics Market Dynamics
  1. 2.1 Glycopeptide Antibiotics Industry Trends
  2. 2.2 Glycopeptide Antibiotics Industry Drivers
  3. 2.3 Glycopeptide Antibiotics Industry Opportunities and Challenges
  4. 2.4 Glycopeptide Antibiotics Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Glycopeptide Antibiotics Market Perspective (2021-2032)
  2. 3.2 Global Glycopeptide Antibiotics Growth Trends by Region
  3. 3.2.1 Global Glycopeptide Antibiotics Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Glycopeptide Antibiotics Market Size by Region (2021-2026)
  5. 3.2.3 Global Glycopeptide Antibiotics Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Glycopeptide Antibiotics Revenue by Players
  2. 4.1.1 Global Glycopeptide Antibiotics Revenue by Players (2021-2026)
  3. 4.1.2 Global Glycopeptide Antibiotics Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Glycopeptide Antibiotics Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Glycopeptide Antibiotics Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Glycopeptide Antibiotics Key Players Headquarters & Area Served
  7. 4.4 Global Glycopeptide Antibiotics Players, Product Type & Application
  8. 4.5 Global Glycopeptide Antibiotics Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Glycopeptide Antibiotics Market CR5 and HHI
  11. 4.6.3 2025 Glycopeptide Antibiotics Tier 1, Tier 2, and Tier 3
5 Glycopeptide Antibiotics Market Size by Type
  1. 5.1 Global Glycopeptide Antibiotics Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Glycopeptide Antibiotics Revenue by Type (2021-2032)
  3. 5.3 Global Glycopeptide Antibiotics Revenue Market Share by Type (2021-2032)
6 Glycopeptide Antibiotics Market Size by Application
  1. 6.1 Global Glycopeptide Antibiotics Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Glycopeptide Antibiotics Revenue by Application (2021-2032)
  3. 6.3 Global Glycopeptide Antibiotics Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Allergan
  2. 7.1.1 Allergan Company Information
  3. 7.1.2 Allergan Business Overview
  4. 7.1.3 Allergan Glycopeptide Antibiotics Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Allergan Glycopeptide Antibiotics Product Portfolio
  6. 7.1.5 Allergan Recent Developments
  7. 7.2 Alvogen
  8. 7.2.1 Alvogen Company Information
  9. 7.2.2 Alvogen Business Overview
  10. 7.2.3 Alvogen Glycopeptide Antibiotics Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Alvogen Glycopeptide Antibiotics Product Portfolio
  12. 7.2.5 Alvogen Recent Developments
  13. 7.3 ANI Pharmaceuticals
  14. 7.3.1 ANI Pharmaceuticals Company Information
  15. 7.3.2 ANI Pharmaceuticals Business Overview
  16. 7.3.3 ANI Pharmaceuticals Glycopeptide Antibiotics Revenue and Gross Margin (2021-2026)
  17. 7.3.4 ANI Pharmaceuticals Glycopeptide Antibiotics Product Portfolio
  18. 7.3.5 ANI Pharmaceuticals Recent Developments
  19. 7.4 Aurobindo Pharma
  20. 7.4.1 Aurobindo Pharma Company Information
  21. 7.4.2 Aurobindo Pharma Business Overview
  22. 7.4.3 Aurobindo Pharma Glycopeptide Antibiotics Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Aurobindo Pharma Glycopeptide Antibiotics Product Portfolio
  24. 7.4.5 Aurobindo Pharma Recent Developments
  25. 7.5 Hikma Pharmaceuticals plc
  26. 7.5.1 Hikma Pharmaceuticals plc Company Information
  27. 7.5.2 Hikma Pharmaceuticals plc Business Overview
  28. 7.5.3 Hikma Pharmaceuticals plc Glycopeptide Antibiotics Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Hikma Pharmaceuticals plc Glycopeptide Antibiotics Product Portfolio
  30. 7.5.5 Hikma Pharmaceuticals plc Recent Developments
  31. 7.6 Lytix Biopharma
  32. 7.6.1 Lytix Biopharma Company Information
  33. 7.6.2 Lytix Biopharma Business Overview
  34. 7.6.3 Lytix Biopharma Glycopeptide Antibiotics Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Lytix Biopharma Glycopeptide Antibiotics Product Portfolio
  36. 7.6.5 Lytix Biopharma Recent Developments
  37. 7.7 Theravance Biopharma
  38. 7.7.1 Theravance Biopharma Company Information
  39. 7.7.2 Theravance Biopharma Business Overview
  40. 7.7.3 Theravance Biopharma Glycopeptide Antibiotics Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Theravance Biopharma Glycopeptide Antibiotics Product Portfolio
  42. 7.7.5 Theravance Biopharma Recent Developments
  43. 7.8 Eli Lilly and Company
  44. 7.8.1 Eli Lilly and Company Company Information
  45. 7.8.2 Eli Lilly and Company Business Overview
  46. 7.8.3 Eli Lilly and Company Glycopeptide Antibiotics Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Eli Lilly and Company Glycopeptide Antibiotics Product Portfolio
  48. 7.8.5 Eli Lilly and Company Recent Developments
  49. 7.9 Shenwei Pharmaceutical
  50. 7.9.1 Shenwei Pharmaceutical Company Information
  51. 7.9.2 Shenwei Pharmaceutical Business Overview
  52. 7.9.3 Shenwei Pharmaceutical Glycopeptide Antibiotics Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Shenwei Pharmaceutical Glycopeptide Antibiotics Product Portfolio
  54. 7.9.5 Shenwei Pharmaceutical Recent Developments
  55. 7.10 Zhejiang Hisun Pharmaceutical Co., Ltd.
  56. 7.10.1 Zhejiang Hisun Pharmaceutical Co., Ltd. Company Information
  57. 7.10.2 Zhejiang Hisun Pharmaceutical Co., Ltd. Business Overview
  58. 7.10.3 Zhejiang Hisun Pharmaceutical Co., Ltd. Glycopeptide Antibiotics Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Zhejiang Hisun Pharmaceutical Co., Ltd. Glycopeptide Antibiotics Product Portfolio
  60. 7.10.5 Zhejiang Hisun Pharmaceutical Co., Ltd. Recent Developments
8 North America
  1. 8.1 North America Glycopeptide Antibiotics Revenue (2021-2032)
  2. 8.2 North America Glycopeptide Antibiotics Revenue by Type (2021-2032)
  3. 8.2.1 North America Glycopeptide Antibiotics Revenue by Type (2021-2026)
  4. 8.2.2 North America Glycopeptide Antibiotics Revenue by Type (2027-2032)
  5. 8.3 North America Glycopeptide Antibiotics Revenue Share by Type (2021-2032)
  6. 8.4 North America Glycopeptide Antibiotics Revenue by Application (2021-2032)
  7. 8.4.1 North America Glycopeptide Antibiotics Revenue by Application (2021-2026)
  8. 8.4.2 North America Glycopeptide Antibiotics Revenue by Application (2027-2032)
  9. 8.5 North America Glycopeptide Antibiotics Revenue Share by Application (2021-2032)
  10. 8.6 North America Glycopeptide Antibiotics Revenue by Country
  11. 8.6.1 North America Glycopeptide Antibiotics Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Glycopeptide Antibiotics Revenue by Country (2021-2026)
  13. 8.6.3 North America Glycopeptide Antibiotics Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Glycopeptide Antibiotics Revenue (2021-2032)
  2. 9.2 Europe Glycopeptide Antibiotics Revenue by Type (2021-2032)
  3. 9.2.1 Europe Glycopeptide Antibiotics Revenue by Type (2021-2026)
  4. 9.2.2 Europe Glycopeptide Antibiotics Revenue by Type (2027-2032)
  5. 9.3 Europe Glycopeptide Antibiotics Revenue Share by Type (2021-2032)
  6. 9.4 Europe Glycopeptide Antibiotics Revenue by Application (2021-2032)
  7. 9.4.1 Europe Glycopeptide Antibiotics Revenue by Application (2021-2026)
  8. 9.4.2 Europe Glycopeptide Antibiotics Revenue by Application (2027-2032)
  9. 9.5 Europe Glycopeptide Antibiotics Revenue Share by Application (2021-2032)
  10. 9.6 Europe Glycopeptide Antibiotics Revenue by Country
  11. 9.6.1 Europe Glycopeptide Antibiotics Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Glycopeptide Antibiotics Revenue by Country (2021-2026)
  13. 9.6.3 Europe Glycopeptide Antibiotics Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Glycopeptide Antibiotics Revenue (2021-2032)
  2. 10.2 China Glycopeptide Antibiotics Revenue by Type (2021-2032)
  3. 10.2.1 China Glycopeptide Antibiotics Revenue by Type (2021-2026)
  4. 10.2.2 China Glycopeptide Antibiotics Revenue by Type (2027-2032)
  5. 10.3 China Glycopeptide Antibiotics Revenue Share by Type (2021-2032)
  6. 10.4 China Glycopeptide Antibiotics Revenue by Application (2021-2032)
  7. 10.4.1 China Glycopeptide Antibiotics Revenue by Application (2021-2026)
  8. 10.4.2 China Glycopeptide Antibiotics Revenue by Application (2027-2032)
  9. 10.5 China Glycopeptide Antibiotics Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Glycopeptide Antibiotics Revenue (2021-2032)
  2. 11.2 Asia Glycopeptide Antibiotics Revenue by Type (2021-2032)
  3. 11.2.1 Asia Glycopeptide Antibiotics Revenue by Type (2021-2026)
  4. 11.2.2 Asia Glycopeptide Antibiotics Revenue by Type (2027-2032)
  5. 11.3 Asia Glycopeptide Antibiotics Revenue Share by Type (2021-2032)
  6. 11.4 Asia Glycopeptide Antibiotics Revenue by Application (2021-2032)
  7. 11.4.1 Asia Glycopeptide Antibiotics Revenue by Application (2021-2026)
  8. 11.4.2 Asia Glycopeptide Antibiotics Revenue by Application (2027-2032)
  9. 11.5 Asia Glycopeptide Antibiotics Revenue Share by Application (2021-2032)
  10. 11.6 Asia Glycopeptide Antibiotics Revenue by Country
  11. 11.6.1 Asia Glycopeptide Antibiotics Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Glycopeptide Antibiotics Revenue by Country (2021-2026)
  13. 11.6.3 Asia Glycopeptide Antibiotics Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Glycopeptide Antibiotics Revenue (2021-2032)
  2. 12.2 SAMEA Glycopeptide Antibiotics Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Glycopeptide Antibiotics Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Glycopeptide Antibiotics Revenue by Type (2027-2032)
  5. 12.3 SAMEA Glycopeptide Antibiotics Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Glycopeptide Antibiotics Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Glycopeptide Antibiotics Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Glycopeptide Antibiotics Revenue by Application (2027-2032)
  9. 12.5 SAMEA Glycopeptide Antibiotics Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Glycopeptide Antibiotics Revenue by Country
  11. 12.6.1 SAMEA Glycopeptide Antibiotics Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Glycopeptide Antibiotics Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Glycopeptide Antibiotics Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst